Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

JB Chemicals Net Plunges 76 Percent in Jun'07 Qtr (India)

This article was originally published in PharmAsia News

Executive Summary

Globally powerful India-based pharmaceutical company JB Chemicals & Pharmaceuticals posted a 76.40 percent net profit decline during second-quarter 2007 ending on June 30 compared to second-quarter 2006. The company's second quarter net sales rose by 4.07 percent, however, while its declining profit still came in at a positive RS 30.71 million crore. This company has worldwide distribution in over 50 countries. Its earnings per share registered at RS 0.36 in second-quarter 2007 compared to RS 1.55 during the same period last year. (Click here for more

You may also be interested in...



Canadian Body Addresses Shortages Risk

The CGPA and Biosimilars Canada have acknowledged the risk of local shortages amid the coronavirus crisis, after Health Canada advised Canadians that buying more medicine than usual could lead to local supply disruptions.

Circassia Ends AZ Deal To Dig Itself Out Of Debt Hole

Circassia is returning the US rights to two COPD drugs to AstraZeneca as it admits it cannot meet its debt payments from the deal.

Regulators Insist On Large-Scale Trials For Coronavirus Treatment Candidates

At their second meeting on COVID-19, drug regulators from around the world have stressed the importance of large, multi-arm studies in generating the data needed for the approval of potential coronavirus therapies. The European Medicines Agency, which organized the meeting, has also announced a new coronavirus task force to identify promising drug candidates and help steer them through development to regulatory approval.

UsernamePublicRestriction

Register

SC066397

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel